UPDATE: CPHI Barcelona 2023 Innovator Interview – Hangzhou Huishi Consulting

Our Innovator Interviews takes a look at the cutting-edge strategies and technologies being implemented within the pharmaceutical supply chain through an in-depth discussion with a leading innovator in the industry. 

Questions

1. Could you give us an overview of your company and what your role is? 

2. What are you bringing to CPHI Barcelona this year? 

3. What is the current state of generics development, and what challenges is the pharma industry encountering in this sector? 

4. What makes excipients an important area of focus for the pharma industry right now? 

5. Could you give an overview of the technology utilised to develop common generics and their excipients? How are these technologies themselves developing? 

6. How do events like CPHI Barcelona help companies like yours with their business goals? 

7. What are you most looking forward to at CPHI Barcelona this year? 

At CPHI Barcelona, we caught up with Mr Li Wenbo, CEO of Hangzhou Huishi Consulting, to further discuss the importance of events such as CPHI and the innovative technologies they brought with them.

Thank you for joining me today Mr Li. Is this your first time in Barcelona?

Li: Yes, this is my first time in Barcelona and it is very important for our company to be here. 

What have been your highlights on the road to CPHI Barcelona?

Li: During this period, we've joined in a Chinese domestic API exhibition in Nanjing, and we've found that Chinese pharmaceutical companies are very interested in exploring the market abroad.

Have there been any trending topics of discussion in your meetings with others at this event?

Li: The main topics we've discussed are about product quality control. We all know that in vivo absorption of oral solid formulations is highly related to in vitro disintegration and dissolution. These indicators are directly influenced by the crystal form, particle size, and other functionality-related characteristics of the raw materials and excipients.

What challenges and issues have been discussed around excipient development?

Li: The main challenge that everyone agrees on is that in order to achieve better quality control, it is necessary to find testing methods that can quantify these indicators. However, the current pharmacopoeia does not specify these standards.

What solutions have you discussed to address these issues?

Li: With the aim of achieving the expected therapeutic effect and reducing corresponding adverse reactions in patients after taking the medicine, risk assessment analysis is conducted on the key quality attributes of the formulation to obtain the key characteristics of which excipients are involved in the prescription. Then establish corresponding testing methods and indicators, of course, these processes will definitely involve the latest testing methods, such as MALDI TOF, high-resolution mass spectrometry, X-ray diffraction etc.

Could you describe CPHI Barcelona in three words?

Li: Inspiring, enthusiastic, professional